ABSTRACT
Digoxin, the oldest known cardiovascular drug, is still used today to treat heart failure and atrial fibrillation. Because it has a narrow therapeutic index and multiple interactions, it frequently causes toxicity with a wide range of symptoms and cardiac arrhythmias. More importantly, elevated serum digoxin levels have been linked to a higher risk of death in patients with heart failure or atrial fibrillation, even without signs or symptoms of toxicity. This article reviews the current state of digoxin use, its pharmacologic principles, and the mechanisms, clinical presentation, and management of toxicity.
Subject(s)
Atrial Fibrillation , Digoxin , Heart Failure , Digoxin/adverse effects , Digoxin/blood , Humans , Atrial Fibrillation/drug therapy , Heart Failure/chemically induced , Cardiotonic Agents/therapeutic use , Cardiotonic Agents/adverse effects , Cardiotonic Agents/pharmacology , Anti-Arrhythmia Agents/adverse effectsABSTRACT
BACKGROUND: Atrial fibrillation (AF) is the most common complication after Coronary Artery Bypass Surgery (CABG). Despite advanced treatment methods, primary prevention is crucial. Many factors have been investigated as markers for AF, but further research is required. CABG is currently superior to Primary Coronary Intervention (PCI) in some cases due to Left Anterior Descending Artery (LAD)- Internal Thoracic Artery (ITA) anastomosis. However, graft choice for non-LAD vessels is still controversial. Our study compared the incidence of arrhythmia between patients with single ITA or bilateral ITA (BITA). METHODS: The study included 84 isolated CABG patients. The patients were divided into two groups: single ITA and BITA. Patients who developed AF were recorded and compared. RESULTS: 73.8%(n = 62) of the patients were male and 26.2%(n = 22) were female. While single ITA was used in 48.8%(n = 41) of the patients, BITA was used in 51.2%(n = 43). AF was detected in 15.5%(n = 13) of the patients. AF was observed in 5(12.2%) patients in the single ITA group and 8(18.6%) in the BITA group. 76.9%(n = 10) of the patients with AF rhythm had Diabetes Mellitus (DM)(p = 0.011). Biphasic P wave, length of P wave duration, and total Morpholog-Voltage-P Wave ECG (MVP ECG) score height were statistically significantly different. CONCLUSIONS: The development of AF was similar in both groups. The presence of DM, high blood glucose levels, and ECG findings can detect a predisposition to postoperative AF. MVP ECG risk score is effective as an AF marker and can be used in surgical patient groups.
Subject(s)
Atrial Fibrillation , Electrocardiography , Mammary Arteries , Humans , Atrial Fibrillation/physiopathology , Atrial Fibrillation/surgery , Female , Male , Middle Aged , Aged , Mammary Arteries/transplantation , Postoperative Complications/epidemiology , Coronary Artery Bypass/adverse effects , Coronary Artery Bypass/methods , Risk Factors , Risk Assessment/methods , Retrospective Studies , Coronary Artery Disease/surgery , IncidenceSubject(s)
Atrial Fibrillation , Channelopathies , Humans , Channelopathies/genetics , Channelopathies/diagnosis , Risk AssessmentABSTRACT
BACKGROUND: New-onset postoperative atrial fibrillation (POAF) is a common complication after coronary artery bypass grafting (CABG) surgery, increasing the risk of embolism and stroke. There is a lack of information on the use of anticoagulants in this context. The choice between Warfarin and Direct oral anticoagulants (DOACs) also is not well-established. This randomized study aimed to compare the feasibility and safety of Warfarin and Rivaroxaban in preventing thrombotic events in POAF patients after isolated CABG. METHODS: A total of 66 patients were randomized parallelly with 1:1 allocation to receive either Rivaroxaban (n = 34) or Warfarin (n = 32). Major bleeding events within 30 days after discharge were the primary outcome. Secondary outcomes included minor bleeding events and thrombotic episodes. Clinical characteristics, medication regimens, and left atrial diameter were assessed. Statistical analyses were performed using appropriate tests. RESULTS: No thrombotic episodes were observed in either treatment arm. No major bleeding events occurred in either group. Four minor bleeding events were reported, with no significant difference between the treatment groups (P = 0.6). Patients with atrial fibrillation had significantly larger left atrial diameters compared to those with normal sinus rhythm (40.5 vs. 37.8 mm, P = 0.01). CONCLUSIONS: This pilot study suggests that Warfarin and Rivaroxaban are both safe and effective for preventing thrombotic episodes in POAF patients after isolated CABG. No significant differences in major bleeding events were observed between the two anticoagulants. These findings may support the preference for DOACs like Rivaroxaban due to their convenience and easier maintenance. TRIAL REGISTRATION: Number IRCT20200304046696N1, Date 18/03/2020 https//irct.behdasht.gov.ir/ .
Subject(s)
Anticoagulants , Atrial Fibrillation , Coronary Artery Bypass , Factor Xa Inhibitors , Hemorrhage , Rivaroxaban , Warfarin , Humans , Atrial Fibrillation/diagnosis , Atrial Fibrillation/etiology , Atrial Fibrillation/prevention & control , Atrial Fibrillation/drug therapy , Atrial Fibrillation/physiopathology , Pilot Projects , Male , Coronary Artery Bypass/adverse effects , Female , Aged , Middle Aged , Rivaroxaban/adverse effects , Rivaroxaban/administration & dosage , Treatment Outcome , Warfarin/adverse effects , Warfarin/administration & dosage , Warfarin/therapeutic use , Time Factors , Factor Xa Inhibitors/adverse effects , Factor Xa Inhibitors/administration & dosage , Anticoagulants/adverse effects , Anticoagulants/administration & dosage , Anticoagulants/therapeutic use , Hemorrhage/chemically induced , Feasibility Studies , Risk Factors , Coronary Artery Disease/surgerySubject(s)
Atrial Fibrillation , Pneumonectomy , Postoperative Complications , Humans , Atrial Fibrillation/etiology , Atrial Fibrillation/surgery , Pneumonectomy/adverse effects , Postoperative Complications/epidemiology , Postoperative Complications/etiology , Risk Factors , Lung Neoplasms/surgeryABSTRACT
AIM: To evaluate the prognostic value of GDF-15 in relation the development of bleeding and events in stable CAD patients, receiving combined antithrombotic therapy. MATERIALS AND METHODS: The data was obtained from the prospective registry REGATA, 343 CAD patients (249 males), median age 68 [IQR 62; 75] years) were enrolled. Patients with sinus rhythm and concomitant PAD received acetylsalicylic acid in combination with rivaroxaban 2.5 mg bid (31.8%) or clopidogrel (24.8%). Other 43.4% with concomitant atrial fibrillation (AF) received direct oral anticoagulants in combination with antiplatelet therapy after elective percutaneous coronary interventions. Median follow-up was 12 months [IQR 9.0; 18.0]. The safety end point was major and clinically relevant bleedings (type 2-5) according to the BARC classification. Plasma samples for GDF-15 identification were taken at the inclusion and analyzed using ELISA assay. RESULTS: Frequency of BARC 2-5 bleedings was 16% (BARC 2 - 46; BARC 3 - 9; BARC 4-5 - 0), median GDF-15 level was 1185.0 pg/ml [850.0; 1680.0]. In patients with AF and concomitant MFA, the level of GDF-15 was significantly higher than in the subgroups of patients with only AF or MFA (p=0.0022). According to the quintile analysis, GDF-15 values in the top three quintiles of distribution (cut-off value >943 pg/ml) were associated with higher frequency of bleeding events: 23.2% versus 5.1%; p=0.0001. The multivariable logistic regression model demonstrated that bleeding events were independently associated with GDF-15 level>943 pg/ml (OR 2.65, 95% CI 1.11-6.30; p=0.0275), AF (OR 2.61, 95% CI 1.41-4.83; p=0.0023) and chronic kidney disease (OR 1.92, 95% CI 1.03-3.60; p=0.0401). Clinical factors determining the risk of bleeding events also determined a GDF-15 elevation. CONCLUSION: Assessment of GDF-15 level may improve bleeding risk stratification in CAD patients with concomitant AF and/or PAD receiving combined antithrombotic therapy.
Subject(s)
Growth Differentiation Factor 15 , Hemorrhage , Registries , Humans , Male , Female , Aged , Hemorrhage/chemically induced , Hemorrhage/epidemiology , Hemorrhage/etiology , Middle Aged , Growth Differentiation Factor 15/blood , Prospective Studies , Coronary Artery Disease/complications , Coronary Artery Disease/blood , Drug Therapy, Combination , Atrial Fibrillation/drug therapy , Atrial Fibrillation/complications , Fibrinolytic Agents/administration & dosage , Fibrinolytic Agents/adverse effects , Aspirin/administration & dosage , Aspirin/adverse effects , Clopidogrel/administration & dosage , Clopidogrel/adverse effects , Prognosis , Russia/epidemiology , Platelet Aggregation Inhibitors/administration & dosage , Platelet Aggregation Inhibitors/adverse effects , Rivaroxaban/administration & dosage , Rivaroxaban/adverse effects , Percutaneous Coronary Intervention/methods , Percutaneous Coronary Intervention/adverse effectsABSTRACT
AIM: To evaluate the efficacy and safety of the advanced technique for positioning the endocardial electrodes of a cardiac contractility modulation (CCM) device. MATERIALS AND METHODS: The CCM system was implanted in 100 patients, of which 60 CCM electrodes were positioned in the most optimal zones of myocardial perfusion, in particular, in the zone of the minor focal-scar/fibrotic lesion (the Summed Rest Score of 0 to 1-2, the intensity of the radiopharmaceutical at least 30%), and in 40 patients according to the standard procedure. Before the implantation of the CCM system, 60 patients underwent tomography (S-SPECT) of the myocardium with 99mTc-methoxy-isobutyl-isonitrile at rest to determine the most optimal electrode positioning zones and 100 patients underwent transthoracic echocardiography at baseline and after 12 months to assess the effectiveness of surgical treatment. RESULTS: Improved ventricular electrode positioning technique is associated with the best reverse remodeling of the left ventricular myocardium, especially in patients with ischemic chronic heart failure, with less radiation exposure to the surgeon and the patient, and without electrode-related complications. CONCLUSION: At the preoperative stage, it is recommended to perform a synchronized single-photon emission computed tomography of the myocardium with 99mTc-methoxy-isobutyl-isonitrile at rest before implantation of the CCM device to assess the presence of scar zones/myocardial fibrosis in the anterior and inferior septal regions of the interventricular septum of the left ventricle, followed by implantation of ventricular electrodes in the zone of the minor scar/fibrous lesion, which will allow to achieve optimal stimulation parameters, increase the effectiveness of CCM therapy, reduce the radiation exposure on medical personnel and the patient during surgery.
Subject(s)
Atrial Fibrillation , Heart Failure , Humans , Male , Female , Middle Aged , Heart Failure/physiopathology , Heart Failure/therapy , Atrial Fibrillation/physiopathology , Atrial Fibrillation/therapy , Atrial Fibrillation/surgery , Aged , Treatment Outcome , Electrodes, Implanted , Stroke Volume/physiology , Tomography, Emission-Computed, Single-Photon/methods , Echocardiography/methods , Myocardial Contraction/physiologyABSTRACT
BACKGROUND: There are no randomized studies comparing the maintenance of sinus rhythm after catheter ablation (CA) concerning treatment with antiarrhythmic drugs (AA) in elderly patients with paroxysmal atrial fibrillation (AF). OBJECTIVES: To compare the clinical results of pulmonary vein (PV) isolation with the second-generation PVAC Gold catheter against AA treatment in elderly people with recurrent symptomatic paroxysmal AF, refractory to at least one AA, and without structural heart disease. METHODS: Sixty patients with paroxysmal AF ≥ 65 years old were randomized to two forms of treatment: group 1: CA and group 2: AA drugs. The primary outcome was the AF recurrence-free rate after at least one year of follow-up. Secondary outcomes were: progression to persistent forms of AF, impact on quality of life (QOLF), and complications. The significance level adopted in the statistical analysis was 5% (p<0.05). RESULTS: The AF recurrence-free rate was 80% (10% with amiodarone) in the CA group, after 1.3 procedures per patient and 65% in the AA group (60% with amiodarone), (p = 0.119) in an average follow-up of 719 days (Q1: 566; Q3: 730). The persistent AF free rate was 83.4% in the AC group and 67.7% in the AA group (p = 0.073) Both strategies showed an improvement in the AFQoL score during follow-up (p < 0.001), with no difference between the groups. Although without clinical repercussions or impact on the intellectual assessment test, 25% of patients in the CA group showed signs of cerebral embolization on brain MRI. CONCLUSIONS: Both strategies for maintaining sinus rhythm promoted an improvement in the quality of life of elderly patients with symptomatic AF, with no statistical difference in the clinical outcomes. Additional studies using technologies with a better safety profile are needed to evaluate the benefits of CA in elderly patients with AF.
FUNDAMENTO: Não existem estudos randomizados comparando a manutenção do ritmo sinusal após ablação por cateter (AC) em relação ao tratamento com fármacos antiarrítmicos (AA) em pacientes idosos portadores fibrilação atrial (FA) paroxística. OBJETIVOS: Comparar os resultados clínicos do isolamento das veias pulmonares (VPs) com o cateter PVAC Gold de segunda geração com o uso de AA em idosos com FA paroxística sintomática, recorrente, apesar do uso de fármacos AA. MÉTODOS: Sessenta pacientes com FA paroxística ≥ 65 anos e sem cardiopatias estruturais foram randomizados para duas formas de tratamento: grupo 1: AC e grupo 2: AA. O desfecho primário foi a taxa livre de recorrência de FA após pelo menos um ano de seguimento. Os desfechos secundários foram: progressão para formas persistentes de FA, impacto na qualidade de vida (QVFA) e complicações. O nível de significância adotado na análise estatística foi de 5% (p<0,05). RESULTADOS: A taxa livre de recorrência de FA foi de 80% (10% com amiodarona) no grupo AC, após 1,3 procedimentos por paciente e de 65% no grupo AA (60% com amiodarona), (p = 0,119) num seguimento médio de 719 dias (Q1: 566; Q3: 730). A taxa livre de FA persistente foi de 83,4% no grupo AC e de 67,7% no grupo AA (p = 0,073). Ambas as estratégias apresentaram melhora no escore de QVFA durante o seguimento (p < 0,001), sem diferença entre os grupos. Embora sem repercussão clínica ou impacto no teste de avaliação intelectual, 25% dos pacientes do grupo PVAC apresentou sinais de embolização cerebral na RNM cerebral. CONCLUSÕES: Ambas as estratégias para manutenção do ritmo sinusal promoveram melhora na qualidade de vida de pacientes idosos com FA sintomática, sem diferença estatística nos desfechos clínicos preconizados. Estudos adicionais usando tecnologias com melhor perfil de segurança são necessários para avaliar os benefícios da AC em pacientes idosos com FA.
Subject(s)
Anti-Arrhythmia Agents , Atrial Fibrillation , Catheter Ablation , Pulmonary Veins , Quality of Life , Humans , Atrial Fibrillation/surgery , Atrial Fibrillation/drug therapy , Atrial Fibrillation/therapy , Atrial Fibrillation/physiopathology , Anti-Arrhythmia Agents/therapeutic use , Female , Male , Aged , Catheter Ablation/methods , Treatment Outcome , Pulmonary Veins/surgery , Recurrence , Amiodarone/therapeutic use , Time FactorsABSTRACT
BACKGROUND: Direct oral anticoagulants (DOACs) have been the drug of choice for preventing ischemic stroke in patients with atrial fibrillation since 2014. In previous studies, the stroke risk while taking warfarin was 2 per 100 patient-years and 1.5% per year while taking DOACs. We hypothesized that even if ischemic stroke occurred during anticoagulation therapy with DOACs, the prognosis was likely to be better than that with warfarin. METHODS AND RESULTS: Data from 2002 to 2019, sourced from a nationwide claims database, were used to identify atrial fibrillation patients using International Classification of Diseases codes. Patients who experienced an ischemic stroke during anticoagulation were categorized by the drugs used (warfarin, dabigatran, apixaban, rivaroxaban, and edoxaban). The primary outcome was mortality within 3 months and 1 year after the ischemic stroke. Among the 9578 patients with ischemic stroke during anticoagulation, 3343 received warfarin, and 6235 received DOACs (965 dabigatran, 2320 apixaban, 1702 rivaroxaban, 1248 edoxaban). The DOACs group demonstrated lower risks of 3-month (adjusted hazard ratio [HR], 0.550, [95% CI, 0.473-0.639]; P<0.0001) and 1-year mortality (adjusted HR, 0.596 [95% CI, 0.536-0.663]; P<0.0001) than the warfarin group. Apixaban and edoxaban within the DOAC group exhibited particularly reduced 1-year mortality risk compared with other DOACs (P<0.0001). CONCLUSIONS: Our study confirmed that DOACs have a better prognosis than warfarin after ischemic stroke. The apixaban and edoxaban groups had a lower risk of death after ischemic stroke than the other DOAC groups.
Subject(s)
Anticoagulants , Atrial Fibrillation , Factor Xa Inhibitors , Ischemic Stroke , Warfarin , Humans , Warfarin/therapeutic use , Warfarin/adverse effects , Ischemic Stroke/prevention & control , Ischemic Stroke/mortality , Ischemic Stroke/diagnosis , Male , Female , Aged , Anticoagulants/adverse effects , Anticoagulants/therapeutic use , Anticoagulants/administration & dosage , Atrial Fibrillation/drug therapy , Atrial Fibrillation/complications , Atrial Fibrillation/mortality , Prognosis , Administration, Oral , Factor Xa Inhibitors/therapeutic use , Factor Xa Inhibitors/adverse effects , Factor Xa Inhibitors/administration & dosage , Middle Aged , Aged, 80 and over , Pyridones/adverse effects , Pyridones/therapeutic use , Pyridones/administration & dosage , Retrospective Studies , Pyrazoles/therapeutic use , Pyrazoles/adverse effects , Dabigatran/therapeutic use , Dabigatran/adverse effects , Dabigatran/administration & dosage , Rivaroxaban/therapeutic use , Rivaroxaban/adverse effects , Rivaroxaban/administration & dosage , Risk Factors , Risk Assessment , Taiwan/epidemiology , Pyridines , ThiazolesABSTRACT
The pro- and antiarrhythmic effects of omega-3 polyunsaturated fatty acids (n-3 PUFAs) have been extensively studied in preclinical and human trials. Despite early evidence of an antiarrhythmic role of n-3 PUFA in the prevention of sudden cardiac death and postoperative and persistent atrial fibrillation (AF), subsequent well-designed randomized trials have largely not shown an antiarrhythmic benefit. Two trials that tested moderate and high-dose n-3 PUFA demonstrated a reduction in sudden cardiac death, but these findings have not been widely replicated, and the potential of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) to reduce arrhythmic death in combination, or as monotherapy, remains uncertain. The accumulated clinical evidence does not support supplementation of n-3 PUFA for postoperative AF or secondary prevention of AF. Several large, contemporary, randomized controlled trials of high-dose n-3 PUFA for primary or secondary cardiovascular prevention have demonstrated a small, significant, dose-dependent increased risk of incident AF compared with mineral oil or corn oil comparator. These findings were reproduced with both icosapent ethyl monotherapy and a mixed EPA+DHA formulation. The proarrhythmic mechanism of increased AF in contemporary cohorts exposed to high-dose n-3 PUFA is unknown. EPA and DHA and their metabolites have pleiotropic cardiometabolic and pro- and antiarrhythmic effects, including modification of the lipid raft microenvironment; alteration of cell membrane structure and fluidity; modulation of sodium, potassium, and calcium currents; and regulation of gene transcription, cell proliferation, and inflammation. Further characterization of the complex association between EPA, EPA+DHA, and DHA and AF is needed. Which formulations, dose ranges, and patient subgroups are at highest risk, remain unclear.
Subject(s)
Arrhythmias, Cardiac , Fatty Acids, Omega-3 , Humans , Fatty Acids, Omega-3/therapeutic use , Arrhythmias, Cardiac/prevention & control , Animals , Atrial Fibrillation/prevention & control , Atrial Fibrillation/drug therapy , Death, Sudden, Cardiac/prevention & control , Death, Sudden, Cardiac/etiology , Anti-Arrhythmia Agents/therapeutic use , Dietary Supplements , Eicosapentaenoic Acid/analogs & derivatives , Eicosapentaenoic Acid/therapeutic use , Randomized Controlled Trials as Topic , Docosahexaenoic Acids/therapeutic useABSTRACT
The E-twenty-six variant 1 (ETV1)-dependent transcriptome plays an important role in atrial electrical and structural remodelling and the occurrence of atrial fibrillation (AF), but the underlying mechanism of ETV1 in AF is unclear. In this study, cardiomyocyte-specific ETV1 knockout (ETV1f/fMyHCCre/+, ETV1-CKO) mice were constructed to observe the susceptibility to AF and the underlying mechanism in AF associated with ETV1-CKO mice. AF susceptibility was examined by intraesophageal burst pacing, induction of AF was increased obviously in ETV1-CKO mice than WT mice. Electrophysiology experiments indicated shortened APD50 and APD90, increased incidence of DADs, decreased density of ICa,L in ETV1-CKO mice. There was no difference in VINACT,1/2 and VACT,1/2, but a significantly longer duration of the recovery time after inactivation in the ETV1-CKO mice. The recording of intracellular Ca2+ showed that there was significantly increased in the frequency of calcium spark, Ca2+ transient amplitude, and proportion of SCaEs in ETV1-CKO mice. Reduction of Cav1.2 rather than NCX1 and SERCA2a, increase RyR2, p-RyR2 and CaMKII was reflected in ETV1-CKO group. This study demonstrates that the increase in calcium spark and SCaEs corresponding to Ca2+ transient amplitude may trigger DAD in membrane potential in ETV1-CKO mice, thereby increasing the risk of AF.
Subject(s)
Atrial Fibrillation , Calcium , Heart Atria , Mice, Knockout , Myocytes, Cardiac , Transcription Factors , Animals , Myocytes, Cardiac/metabolism , Mice , Atrial Fibrillation/metabolism , Atrial Fibrillation/genetics , Calcium/metabolism , Heart Atria/metabolism , Transcription Factors/metabolism , Transcription Factors/genetics , DNA-Binding Proteins/metabolism , DNA-Binding Proteins/genetics , Calcium Signaling , Action Potentials , Membrane Potentials , MaleABSTRACT
This case report presents the clinical course and management of a 62-year-old female patient with atrial fibrillation (AF) secondary to levothyroxine overdose along with an underlying secondary infection. The patient was admitted with sudden onset dyspnea, altered sensorium, and neurological deficits. Upon examination, she exhibited tachycardia, irregular heart sounds, and extensive crepitations in the respiratory system. Her electrocardiogram (ECG) showed an absent P wave with a varying RR interval. Laboratory investigations revealed abnormal thyroid function tests (TFTs) and raised polymorphonuclear cells, in addition to hyperglycemia. The patient was managed in the intensive care unit (ICU) with bilevel positive airway pressure (BiPAP) and supplemental oxygen, treated for AF with intravenous (IV) amiodarone, and her blood sugar was controlled with insulin infusion. Discontinuation of levothyroxine therapy was advised. Subsequently, her AF was terminated, and sinus rhythm was restored. Her neurological examination showed right-sided hemiplegia with aphasia. After 1 week of treatment, her TFTs normalized, and she was discharged on appropriate medication.
Subject(s)
Atrial Fibrillation , Drug Overdose , Thyroxine , Humans , Female , Atrial Fibrillation/drug therapy , Middle Aged , Thyroxine/administration & dosage , Thyroxine/therapeutic use , Drug Overdose/diagnosis , Drug Overdose/complications , Electrocardiography , Amiodarone/administration & dosage , Amiodarone/adverse effectsSubject(s)
Atrial Fibrillation , Cardiac Surgical Procedures , Postoperative Complications , Humans , Atrial Fibrillation/mortality , Female , Male , Cardiac Surgical Procedures/mortality , Cardiac Surgical Procedures/adverse effects , Cardiac Surgical Procedures/statistics & numerical data , Postoperative Complications/mortality , Postoperative Complications/epidemiology , Aged , Sex Factors , Middle Aged , Risk FactorsABSTRACT
BACKGROUND: Atrial fibrillation (AF) and obesity coexist in approximately 37.6 million and 650 million people globally, respectively. The anatomical and physiological changes in individuals with obesity may influence the pharmacokinetic properties of drugs. AIM: This review aimed to describe the evidence of the effect of obesity on the pharmacokinetics of antiarrhythmics in people with AF. METHODS: Three databases were searched from inception to June 2023. Original studies that addressed the use of antiarrhythmics in adults with AF and concomitant obesity were included. RESULTS: A total of 4549 de-duplicated articles were screened, and 114 articles underwent full-text review. Ten studies were included in this narrative synthesis: seven cohort studies, two pharmacokinetic studies, and a single case report. Samples ranged from 1 to 371 participants, predominately males (41%-85%), aged 59-75 years, with a body mass index (BMI) of 23-66 kg/m2. The two most frequently investigated antiarrhythmics were amiodarone and dofetilide. Other drugs investigated included diltiazem, flecainide, disopyramide, propafenone, dronedarone, sotalol, vernakalant, and ibutilide. Findings indicate that obesity may affect the pharmacokinetics of amiodarone and sodium channel blockers (e.g., flecainide, disopyramide, and propafenone). Factors such as drug lipophilicity may also influence the pharmacokinetics of the drug and the need for dose modification. DISCUSSION: Antiarrhythmics are not uniformly affected by obesity. This observation is based on heterogeneous studies of participants with an average BMI and poorly controlled confounding factors such as multimorbidity, concomitant medications, varying routes of administration, and assessment of obesity. Controlled trials with stratification at the time of recruitment for obesity are necessary to determine the significance of these findings.
Subject(s)
Anti-Arrhythmia Agents , Atrial Fibrillation , Obesity , Humans , Atrial Fibrillation/drug therapy , Obesity/complications , Obesity/drug therapy , Anti-Arrhythmia Agents/pharmacokinetics , Anti-Arrhythmia Agents/therapeutic use , Middle AgedABSTRACT
AIMS: Catheter ablation (CA) is a well-established treatment option for atrial fibrillation (AF), where sedation and analgesia are pivotal for patient comfort and lesion formation. The impact of anaesthesia type on AF recurrence rates remains uncertain. This study aimed to examine AF recurrence rates depending on conscious sedation (CS) vs. general anaesthesia (GA) during CA. METHODS AND RESULTS: Utilizing nationwide data from the Danish healthcare registries, we conducted this cohort study involving adults (≥18 years) undergoing first-time CA for AF between 2010 and 2018. Patients were categorized by anaesthesia type (CS or GA), with the primary endpoint being AF recurrence, defined by a composite endpoint of either antiarrhythmic drug (AAD) prescriptions, AF-related hospital admissions, electrical cardioversions, or AF re-ablation. The impact of anaesthesia type was evaluated using multivariable Cox proportional hazards analysis. The study cohort comprised 7957 (6421 CS and 1536 GA) patients. Persistent AF, hypertension, and heart failure, as well as use of AAD, were more prevalent in the GA group. Cumulative incidences of recurrent AF were higher in the CS group at 1 (46% vs. 37%) and at 5 (68% vs. 63%) years. Multivariate analysis revealed CS as significantly associated with increased risk of AF recurrence at 5-year follow-up [hazard ratio 1.26 (95% confidence interval 1.15-1.38)], consistent across paroxysmal and persistent AF subtypes. CONCLUSION: This nationwide cohort study suggests a higher risk of AF recurrence with CS during CA compared to GA. These results advocate for considering GA as the preferred anaesthesia type for improved CA outcomes.
Subject(s)
Anesthesia, General , Atrial Fibrillation , Catheter Ablation , Conscious Sedation , Recurrence , Registries , Humans , Atrial Fibrillation/surgery , Atrial Fibrillation/epidemiology , Male , Female , Denmark/epidemiology , Anesthesia, General/statistics & numerical data , Middle Aged , Catheter Ablation/statistics & numerical data , Conscious Sedation/statistics & numerical data , Aged , Treatment Outcome , Risk Factors , Anti-Arrhythmia Agents/therapeutic useSubject(s)
Atrial Fibrillation , Bioprosthesis , Fibrinolytic Agents , Heart Valve Prosthesis , Registries , Humans , Atrial Fibrillation/drug therapy , Heart Valve Prosthesis/adverse effects , Fibrinolytic Agents/therapeutic use , Fibrinolytic Agents/administration & dosage , Prospective Studies , Heart Valve Prosthesis Implantation/instrumentation , Heart Valve Prosthesis Implantation/adverse effectsABSTRACT
Chronic kidney disease (CKD) remains a significant global health issue and is a leading cause of mortality worldwide. Patients with CKD have an increased risk of developing atrial fibrillation (AF) and venous thromboembolism (VTE). While direct oral anticoagulants (DOACs) have become a standard of care for anticoagulation (AC) in patients with AF and VTE, the appropriate use of these agents in comorbid kidney impairment warrants detailed discussion. This scientific narrative review summarizes the effectiveness and safety of apixaban use in patients with renal dysfunction by assessing the current published pharmacokinetic, interventional, observational, and guideline data. Apixaban is a highly selective, orally active, direct inhibitor of factor Xa, with well-established pharmacokinetics and consistent clinical outcomes across a broad range of patient populations, including those with kidney impairment. Overall, the scientific literature has shown that apixaban has a favorable clinical efficacy and safety profile compared with vitamin K antagonists for patients with AF or VTE and comorbid kidney impairment. These data support the approved label dosing strategy of apixaban in reducing the risk of stroke/systemic embolism in patients with nonvalvular AF and in treating VTE across all ranges of kidney function. Both clinician experience and knowledge of patient-specific factors may be required in the management of comorbid patients with advanced CKD or those requiring dialysis, as data on these patients are limited.
Subject(s)
Atrial Fibrillation , Factor Xa Inhibitors , Pyrazoles , Pyridones , Renal Insufficiency, Chronic , Venous Thromboembolism , Humans , Pyridones/pharmacokinetics , Pyridones/adverse effects , Pyridones/therapeutic use , Pyridones/administration & dosage , Pyrazoles/pharmacokinetics , Pyrazoles/therapeutic use , Pyrazoles/adverse effects , Pyrazoles/administration & dosage , Factor Xa Inhibitors/pharmacokinetics , Factor Xa Inhibitors/adverse effects , Factor Xa Inhibitors/therapeutic use , Factor Xa Inhibitors/administration & dosage , Atrial Fibrillation/drug therapy , Atrial Fibrillation/complications , Renal Insufficiency, Chronic/complications , Renal Insufficiency, Chronic/drug therapy , Venous Thromboembolism/drug therapy , Stroke/prevention & control , Stroke/epidemiology , Observational Studies as Topic , Anticoagulants/adverse effects , Anticoagulants/pharmacokinetics , Anticoagulants/therapeutic use , Anticoagulants/administration & dosageABSTRACT
BACKGROUND: Percutaneous left atrial appendage closure (LAAC) has been suggested as an alternative to long-term oral anticoagulation for nonvalvular atrial fibrillation, but comparative data remain scarce. We aimed to assess ischemic and bleeding outcomes of LAAC compared with vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) for the prevention of cardioembolic events in patients with atrial fibrillation. METHODS AND RESULTS: Embase and MEDLINE were searched for randomized trials comparing LAAC, VKAs, and DOACs. The primary efficacy end point was any stroke or systemic embolism. Treatment effects were calculated from a network meta-analysis and ranked according to the surface under the cumulative ranking curve. Seven trials and 73 199 patients were included. The risk of the primary end point was not statistically different between LAAC versus VKAs (odds ratio [OR], 0.92 [95% CI, 0.62-1.50]) and LAAC versus DOACs (OR, 1.11 [95% CI, 0.71-1.73]). LAAC and DOACs resulted in similar risk of major or minor (OR, 0.93 [95% CI, 0.61-1.42]) and major bleeding (OR, 0.92 [95% CI, 0.58-1.46]); however, after exclusion of procedural bleeding, bleeding risk was significantly lower in those undergoing LAAC. Both LAAC and DOACs reduced the risk of all-cause death compared with VKAs (LAAC versus VKAs: OR, 0.70 [95% CI, 0.53-0.91]; DOACs versus VKAs: OR, 0.90 [95% CI, 0.85-0.95], respectively). DOACs ranked as the best treatment for stroke or systemic embolism prevention (66.9%) and LAAC for reducing major bleeding (63.9%) and death (96.4%). CONCLUSIONS: As a nonpharmacological alternative to oral anticoagulation for atrial fibrillation, LAAC showed similar efficacy and safety compared with VKAs or DOACs. Prospective confirmation from larger studies is warranted.
Subject(s)
Anticoagulants , Atrial Fibrillation , Left Atrial Appendage Closure , Humans , Administration, Oral , Anticoagulants/therapeutic use , Anticoagulants/administration & dosage , Anticoagulants/adverse effects , Atrial Fibrillation/complications , Atrial Fibrillation/therapy , Hemorrhage/chemically induced , Left Atrial Appendage Closure/adverse effects , Left Atrial Appendage Closure/methods , Network Meta-Analysis , Risk Factors , Stroke/prevention & control , Stroke/etiology , Treatment OutcomeABSTRACT
AIMS: Physiological activation of the heart using algorithms to minimize right ventricular pacing (RVPm) may be an effective strategy to reduce adverse events in patients requiring anti-bradycardia therapies. This systematic review and meta-analysis aimed to evaluate current evidence on clinical outcomes for patients treated with RVPm algorithms compared to dual-chamber pacing (DDD). METHODS AND RESULTS: We conducted a systematic search of the PubMed database. The predefined endpoints were the occurrence of persistent/permanent atrial fibrillation (PerAF), cardiovascular (CV) hospitalization, all-cause death, and adverse symptoms. We also aimed to explore the differential effects of algorithms in studies enrolling a high percentage of atrioventricular block (AVB) patients. Eight studies (7229 patients) were included in the analysis. Compared to DDD pacing, patients using RVPm algorithms showed a lower risk of PerAF [odds ratio (OR) 0.74, 95% confidence interval (CI) 0.57-0.97] and CV hospitalization (OR 0.77, 95% CI 0.61-0.97). No significant difference was found for all-cause death (OR 1.01, 95% CI 0.78-1.30) or adverse symptoms (OR 1.03, 95% CI 0.81-1.29). No significant interaction was found between the use of the RVPm strategy and studies enrolling a high percentage of AVB patients. The pooled mean RVP percentage for RVPm algorithms was 7.96% (95% CI 3.13-20.25), as compared with 45.11% (95% CI 26.64-76.38) of DDD pacing. CONCLUSION: Algorithms for RVPm may be effective in reducing the risk of PerAF and CV hospitalization in patients requiring anti-bradycardia therapies, without an increased risk of adverse symptoms. These results are also consistent for studies enrolling a high percentage of AVB patients.